NO306457B1 - 2,4-disulfonylfenylbutylnitron, salter derav, farmasöytisk sammensetning, samt anvendelse av denne forbindelse til fremstilling av et medikament - Google Patents

2,4-disulfonylfenylbutylnitron, salter derav, farmasöytisk sammensetning, samt anvendelse av denne forbindelse til fremstilling av et medikament

Info

Publication number
NO306457B1
NO306457B1 NO962637A NO962637A NO306457B1 NO 306457 B1 NO306457 B1 NO 306457B1 NO 962637 A NO962637 A NO 962637A NO 962637 A NO962637 A NO 962637A NO 306457 B1 NO306457 B1 NO 306457B1
Authority
NO
Norway
Prior art keywords
nervous system
central nervous
salts
disulfonylphenylbutylnitron
medicament
Prior art date
Application number
NO962637A
Other languages
English (en)
Other versions
NO962637D0 (no
NO962637L (no
Inventor
John M Carney
Original Assignee
Oklahoma Med Res Found
Univ Kentucky Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Med Res Found, Univ Kentucky Res Found filed Critical Oklahoma Med Res Found
Publication of NO962637D0 publication Critical patent/NO962637D0/no
Publication of NO962637L publication Critical patent/NO962637L/no
Publication of NO306457B1 publication Critical patent/NO306457B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/45—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/46—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton having the sulfo groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO962637A 1993-12-23 1996-06-20 2,4-disulfonylfenylbutylnitron, salter derav, farmasöytisk sammensetning, samt anvendelse av denne forbindelse til fremstilling av et medikament NO306457B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/173,579 US5488145A (en) 1993-12-23 1993-12-23 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
PCT/US1994/014545 WO1995017876A2 (en) 1993-12-23 1994-12-22 2,4-disulphophenyl butylnitrone, its salts, and their use as pharmaceutical spintraps

Publications (3)

Publication Number Publication Date
NO962637D0 NO962637D0 (no) 1996-06-20
NO962637L NO962637L (no) 1996-08-13
NO306457B1 true NO306457B1 (no) 1999-11-08

Family

ID=22632663

Family Applications (1)

Application Number Title Priority Date Filing Date
NO962637A NO306457B1 (no) 1993-12-23 1996-06-20 2,4-disulfonylfenylbutylnitron, salter derav, farmasöytisk sammensetning, samt anvendelse av denne forbindelse til fremstilling av et medikament

Country Status (29)

Country Link
US (4) US5488145A (no)
EP (1) EP0736004B1 (no)
JP (3) JP3412821B2 (no)
KR (1) KR100370522B1 (no)
CN (1) CN1070176C (no)
AT (1) ATE192736T1 (no)
AU (1) AU679835B2 (no)
BR (2) BR9408378A (no)
CA (1) CA2179521C (no)
CZ (1) CZ289629B6 (no)
DE (1) DE69424441T2 (no)
DK (1) DK0736004T3 (no)
ES (1) ES2145264T3 (no)
FI (1) FI111718B (no)
GR (1) GR3034134T3 (no)
HK (2) HK1001768A1 (no)
HR (1) HRP950358B1 (no)
HU (1) HU221167B1 (no)
MY (1) MY114178A (no)
NO (1) NO306457B1 (no)
NZ (1) NZ279025A (no)
PL (1) PL185189B1 (no)
PT (1) PT736004E (no)
RU (1) RU2159231C2 (no)
SG (1) SG64903A1 (no)
SK (1) SK282403B6 (no)
TW (1) TW299315B (no)
UA (1) UA45964C2 (no)
WO (1) WO1995017876A2 (no)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723502A (en) * 1985-07-18 1998-03-03 Proctor; Peter H. Topical spin trap composition and method
US5622994A (en) * 1989-10-17 1997-04-22 Oklahoma Medical Research Foundation Spin trapping pharmaceutical compositions and methods for use thereof
EP0496796B1 (en) * 1989-10-17 1994-08-31 Oklahoma Medical Research Foundation Method and compositions for inhibition of disorders associated with oxidative damage
US6002001A (en) * 1991-06-18 1999-12-14 Oklahoma Medical Research Foundation Spin trapping pharmaceutical compositions and methods for use thereof
US20050107366A1 (en) * 1991-06-18 2005-05-19 Carney John M. Spin trapping pharmaceutical compositions and methods for use thereof
US20040208875A1 (en) * 1995-03-15 2004-10-21 Queen's University At Kingston Method for treating amyloidosis
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
ES2185797T3 (es) * 1995-09-11 2003-05-01 Aventis Pharma Inc Nitronas ciclicas y composiciones farmaceuticas que las contienen.
JP3887020B2 (ja) 1995-11-17 2007-02-28 フロリダ インターナショナル ユニバーシティー アズレニルニトロンスピントラッピング剤、ならびにその製造方法および使用方法
EP0949915A4 (en) * 1996-04-17 2001-07-04 Oklahoma Med Res Found TREATMENT OF DEMENTIA ASSOCIATED WITH AIDS VIRUS INFECTION (HIV-1) USING NITRONE-FREE RADICAL TRAPS
KR20000067915A (ko) * 1996-07-19 2000-11-25 센토르 파마슈티칼스, 인크. 푸란 니트론 화합물
TW429241B (en) * 1996-09-26 2001-04-11 Sumitomo Pharma Nitrone derivatives
US6046232A (en) * 1997-10-17 2000-04-04 Centaur Pharmaceuticals, Inc. α-aryl-N-alkylnitrones and pharmaceutical compositions containing the same
AU2226999A (en) * 1998-01-16 1999-08-02 Renovis, Inc. Thiophene nitrone compounds
WO1999036415A1 (en) * 1998-01-16 1999-07-22 Centaur Pharmaceuticals, Inc. Thioether furan nitrone compounds
US6255353B1 (en) * 1998-03-13 2001-07-03 Centaur Pharmaceuticals, Inc. Inhibition of angiogenesis
US6083989A (en) * 1999-05-18 2000-07-04 Centaur Pharmaceuticals, Inc. Aryl nitrone therapeutics for the treatment of inflammatory bowel disease
WO1999059579A1 (en) * 1998-05-19 1999-11-25 Centaur Pharmaceuticals, Inc. Furan nitrone therapeutics for the treatment of inflammatory bowel disease
US6730700B2 (en) * 1998-12-02 2004-05-04 Renovis, Inc. 3,4,5,-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same
UA66401C2 (en) 1998-12-02 2004-05-17 Sentor Pharmaceuticals Inc 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical composition containing the same
EP1616869B1 (en) 1999-01-25 2012-04-04 National Jewish Health Substituted porphyrins and their therapeutic use
IL146143A0 (en) * 1999-04-28 2002-07-25 Univ Kingston Compositions and methods for treating amyloidosis
BR9904931A (pt) * 1999-10-18 2001-06-12 Sergio Teixeira Ferreira Inibição de amiloidoses
US6815425B1 (en) 1999-10-22 2004-11-09 The United States Of America As Represented By The Secretary Of The Army Pharmaceutical composition containing pGLU-GLU-PRO-NH2 and method for treating diseases and injuries to the brain, spinal cord and retina using same
AU1574701A (en) * 1999-10-22 2001-04-30 Wrair Walter Reed Army Institute Of Research A pharmaceutical composition containing pglu-glu-pro-nh2 and method for treating diseases and injuries to the brain, spinal cord and retina using same
SE0000056D0 (sv) * 2000-01-10 2000-01-10 Astrazeneca Ab Novel process
AU2001236442A1 (en) * 2000-01-10 2001-07-24 Centaur Phamaceuticals, Inc. Method for the purification of aryl sulfonic acids and salts
SE0000055D0 (sv) * 2000-01-10 2000-01-10 Centaur Pharmaceuticals Inc Novel process
SE0001916D0 (sv) * 2000-05-23 2000-05-23 Astrazeneca Ab Novel formulation
US6664297B1 (en) 2000-10-18 2003-12-16 Universidade Federal Do Rio De Janeiro Methods for inhibition and dissolution of amyloidoses by administration of compositions comprising 2,4-dinitrophenol
WO2002065993A2 (en) 2001-01-08 2002-08-29 Centaur Pharmaceuticals, Inc. Use of aryl nitrone compounds in methods for treating neuropathic pain
WO2003010154A1 (en) * 2001-07-26 2003-02-06 Samsung Electronics Co. Ltd. Seleno compounds containing nitrone moiety, their preparation and their therapeutic uses
US20030045461A1 (en) * 2001-09-06 2003-03-06 Jen-Chang Hsia Composition and methods of esterified nitroxides gated with carboxylic acids
FR2846968B1 (fr) * 2002-11-08 2005-02-04 Salles Jean Pierre Nouveaux derives amphiphiles de l'alpha-c-phenyl-n-tert- butyl nitrone
US7244764B2 (en) * 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7414076B2 (en) * 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20070010573A1 (en) * 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US20050059638A1 (en) * 2003-08-04 2005-03-17 Kelly Michael G. Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders
US20050182060A1 (en) * 2004-02-13 2005-08-18 Kelly Michael G. 2-Substituted and 4-substituted aryl nitrone compounds
BRPI0517790A (pt) * 2004-11-12 2008-10-21 Neurochem Int Ltd métodos e composições fluoradas para tratar doenças relacionadas à amilóide
US20060167057A1 (en) * 2004-11-16 2006-07-27 Xianqi Kong Compounds for the treatment of CNS and amyloid associated diseases
US8044100B2 (en) * 2004-12-22 2011-10-25 Bellus Health Inc. Methods and compositions for treating amyloid-related diseases
US20060235370A1 (en) * 2005-04-04 2006-10-19 Oblong John E Method of regulating mammalian keratinous tissue
TW200716088A (en) * 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
WO2007013842A1 (en) * 2005-07-26 2007-02-01 Astrazeneca Ab Use of 4-((tert-butylimino)methyl) benzene-1,3-disulfonate n-oxide against maemorrhagic changes in the brain
WO2007013841A1 (en) * 2005-07-26 2007-02-01 Astrazeneca Ab Use of 4-((tert-butylimine)methyl) benzene-1,3-disulfonate n-oxide against cerebral oedema
WO2007013843A1 (en) * 2005-07-26 2007-02-01 Astrazeneca Ab Use of 4-[(tert-butylimino)methyl]benzene-1,3-disulfonate n-oxide against myocardial ischaemia
WO2007013844A1 (en) * 2005-07-26 2007-02-01 Astrazeneca Ab Use of 4-[(tert-butylimino)benzene-1,3-disulfonate n-oxide against nausea
CA2634871A1 (en) * 2005-12-22 2007-11-08 Neurochem (International) Limited Treatment of renal disorders, diabetic nephopathy and dyslipidemias
US8420595B2 (en) * 2006-07-25 2013-04-16 Oklahoma Medical Research Foundation Methods for treating acute acoustic trauma
FI3851447T3 (fi) 2006-10-12 2023-11-15 Bellus Health Inc Menetelmiä, yhdisteitä, koostumuksia ja vehikkeleitä 3-amino-1-propaanisulfonihapon vapauttamiseksi
JP2010529947A (ja) * 2006-12-22 2010-09-02 ベラス ヘルス（インターナショナル）リミテッド 代謝性疾患および糖尿病を治療するための方法、化合物、および組成物
US20090082454A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched disufenton
DE202008018589U1 (de) 2007-09-26 2016-03-14 St. Jude Medical, Inc. Zusammenfaltbare Herzklappenprothesen
AU2009214727B2 (en) 2008-02-12 2014-12-11 Tosk, Incorporated Doxorubicin adjuvants to reduce toxicity and methods for using the same
US11382895B2 (en) * 2008-05-23 2022-07-12 National Jewish Health Methods for treating injury associated with exposure to an alkylating species
ES2398339T3 (es) 2008-09-02 2013-03-15 Oklahoma Medical Research Foundation 2,4-disulfonil fenil terc-butil nitrona para el tratamiento de gliomas
WO2011028503A1 (en) * 2009-08-24 2011-03-10 Hough Ear Institute Methods for treating acute acoustic trauma
ES2893825T3 (es) 2011-02-04 2022-02-10 Hough Ear Inst Métodos de tratamiento de lesiones cerebrales
EP3532042A4 (en) * 2016-10-31 2020-06-24 Hough Ear Institute METHOD FOR IMPROVING SYNAPTOGENESIS AND NEURITOGENESIS
KR20190119046A (ko) 2017-01-19 2019-10-21 오톨로직 파마슈틱스, 인크. N-아세틸시스테인의 제제 및 이의 용도
EP3684345A4 (en) * 2017-09-20 2021-06-23 Oklahoma Medical Research Foundation TREATMENT OF DRUG RESISTANT GLIOMAS
US10829441B2 (en) 2017-11-14 2020-11-10 The University Of Toledo Reactive oxygen species-sensitive nitric oxide synthase inhibitors for the treatment of ischemic stroke
WO2019213245A1 (en) 2018-05-03 2019-11-07 Hough Ear Institute Methods for reducing accumulated pathologic tau protein

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0496796B1 (en) * 1989-10-17 1994-08-31 Oklahoma Medical Research Foundation Method and compositions for inhibition of disorders associated with oxidative damage
US5025032A (en) * 1989-10-17 1991-06-18 Oklahoma Medical Research Foundation Phenyl butyl nitrone compositions and methods for treatment of oxidative tissue damage
US5036097A (en) * 1989-10-17 1991-07-30 Oklahoma Medical Research Foundation Phenylbutyl nitrone compositions and methods for prevention of gastric ulceration
EP0590072B1 (en) * 1991-06-18 2001-12-05 Oklahoma Medical Research Foundation Use of spin trapping for the treatment of diseases associated with oxidation of lipids and proteins
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps

Also Published As

Publication number Publication date
US5475032A (en) 1995-12-12
WO1995017876A3 (en) 1995-08-10
SK78896A3 (en) 1997-09-10
BR9408378A (pt) 1997-08-19
HRP950358B1 (en) 2001-04-30
FI962589A0 (fi) 1996-06-20
PL185189B1 (pl) 2003-03-31
CN1156447A (zh) 1997-08-06
US5488145A (en) 1996-01-30
HRP950358A2 (en) 1997-08-31
AU1552795A (en) 1995-07-17
PL315154A1 (en) 1996-10-14
DE69424441T2 (de) 2000-10-12
FI962589A (fi) 1996-08-20
CZ177596A3 (en) 1996-12-11
US5508305A (en) 1996-04-16
EP0736004A1 (en) 1996-10-09
SK282403B6 (sk) 2002-01-07
US5780510A (en) 1998-07-14
HUT76788A (en) 1997-11-28
RU2159231C2 (ru) 2000-11-20
SG64903A1 (en) 1999-05-25
CZ289629B6 (cs) 2002-03-13
FI111718B (fi) 2003-09-15
HK1008294A1 (en) 1999-05-07
UA45964C2 (uk) 2002-05-15
GR3034134T3 (en) 2000-11-30
KR100370522B1 (ko) 2003-05-16
CN1070176C (zh) 2001-08-29
JP3412821B2 (ja) 2003-06-03
DE69424441D1 (de) 2000-06-15
AU679835B2 (en) 1997-07-10
DK0736004T3 (da) 2000-10-09
HU221167B1 (en) 2002-08-28
NO962637D0 (no) 1996-06-20
TW299315B (no) 1997-03-01
CA2179521C (en) 2002-03-19
MY114178A (en) 2002-08-30
BR1100626A (pt) 1999-11-23
PT736004E (pt) 2000-09-29
JP2004075696A (ja) 2004-03-11
EP0736004B1 (en) 2000-05-10
JPH09507232A (ja) 1997-07-22
HU9601739D0 (en) 1996-08-28
CA2179521A1 (en) 1995-07-06
HK1001768A1 (en) 1998-07-10
NZ279025A (en) 1998-02-26
ATE192736T1 (de) 2000-05-15
NO962637L (no) 1996-08-13
ES2145264T3 (es) 2000-07-01
JP2001010953A (ja) 2001-01-16
WO1995017876A2 (en) 1995-07-06

Similar Documents

Publication Publication Date Title
NO306457B1 (no) 2,4-disulfonylfenylbutylnitron, salter derav, farmasöytisk sammensetning, samt anvendelse av denne forbindelse til fremstilling av et medikament
DE69331409T2 (de) Oral 1alpha-hydroxyprevitamin d
ATE306266T1 (de) Verbesserte verabreichungstechnik für multiple medikamentengaben
UA29469C2 (uk) Ліпосомальна фармацевтична композиція для внутрішньовенного введення
EE04606B1 (et) H+, K+-ATPaasi inhibiitori kasutamine ravimi valmistamiseks peroraalseks manustamiseks
ES2147788T3 (es) 3,4-diarilcromanos para el tratamiento de la dermatitis.
NZ320355A (en) Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6- tetrahydropyridine for preparing drugs for treating amyotrophic lateral sclerosis
AR023687A1 (es) Una composicion para el tratamiento de desordenes de la retina externa y el uso de un antagonista de glutamato para la manufactura de un medicamento parael tratamiento de desordenes de la retina externa
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
HUP9900227A2 (hu) AII-receptor antagonisták új gyógyszerészeti felhasználása
DK0706395T3 (da) Lægemiddel med analgetisk effekt med minimal bevægelsesblokade
GEP20043377B (en) Pharmaceutical Complex
ES2053683T3 (es) Forma de medicamento de aplicacion oral para el tratamiento de la hipertension una vez al dia con hidrocloruro de diltiazem.
WO1994016705A3 (en) Pharmaceutical composition containing 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone and its use for the treatment of cns disorders
DK0950053T3 (da) Hidtil ukendte benzoylalkyl.1,2,3,6-tetrahydropyridinderivater
IT1254707B (it) Uso topico della calcitonima per la preparazione di medicamenti nella cataratta idiopatica senile e una composizione farmaceutica che la contiene
ITMI922969A0 (it) Nuovi peptidi sintetici, processo per la loro preparazione, composizioni farmaceutiche che li contengono e loro impiego per la somministrazione di farmaci attraverso la barriera emato-encefalica e la retina.
MX9400288A (es) Procedimiento para la preparacion de un medicamento util como radiorestaurador.